Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has provided an update.
Shanghai Fosun Pharmaceutical announced that its subsidiary, Suzhou Erye Pharmaceutical Co., Ltd., has received marketing registration approval from the National Medical Products Administration for Compound Sodium Picosulfate Granules. This approval is expected to enhance the company’s product offerings and strengthen its position in the pharmaceutical market, potentially benefiting stakeholders by expanding its portfolio and market reach.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development, manufacture, and sale of pharmaceutical products, with a market focus on both domestic and international markets.
YTD Price Performance: 14.20%
Average Trading Volume: 5,317
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $8.57B
For detailed information about 2196 stock, go to TipRanks’ Stock Analysis page.